Clinical Intelligence
search
Evo2 Genomic Analysis
Map structural differences, identify target genes, and generate comprehensive reports.
biotech
Patient: PT-8829-ASequence Alignment
ReferenceATGCGTACGTAGCTAGCTAGCTAGCTAGCTAGCTAGCTAGCTAGCTAGCTAGCTAGCTAG
PatientATGCGTACGTAGCTAGCTAGCTAGCTAGCTAGCTAGCTAGCTAGCTAGCTAGCTAGCTAG
Consensus************************************************************
ReferenceCTAGCTAGCTAGCTAGCTAGCTAGCTAGCTAGCTAGCTAGCTAGCTAGCTAGCTAGCTAG
PatientCTAGCTAGCTAGCTAGCTAGCTAGCTAGCTAGCTAGCTAGCTAGCTAGCTAGCTAGCTAG
Consensus************************************************************
ReferenceGCTAGCTAGCTAGCTAGCTAGCTAGCTAGCTAGCTAGCTAGCTAGCTAGCTAGCTAGCTA
PatientGCTAGCTAGCTAGCTAGCTAACTAGCTAGCTAGCTAGCTAGCTAGCTAGCTAGCTAGCTA
Consensus******************** ***************************************
Identified Target Genes
| Gene | Mutation | Impact Score | Action |
|---|---|---|---|
| KRAS | G12C | High | |
| TP53 | R273H | Medium |
Preliminary Diagnosis
Primary Finding
Non-Small Cell Lung Cancer (NSCLC) with KRAS G12C mutation.
Evo2 Analysis Summary
The Bio Evo2 model has identified a significant structural difference in the KRAS gene at codon 12, substituting glycine for cysteine. This mutation is a known driver in NSCLC and presents a highly viable target for covalent inhibitors.
Secondary mutations in TP53 suggest a complex tumor profile, potentially affecting response to standard therapies.